-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the progress of centralized procurement of drugs organized by the state to the third round, the effect of price reduction brought about by the normalization and institutionalization of the collection is constantly emerging.
research institutions said that the price reduction of state-organized drug collection gradually stabilized, on average around 50%.
background, domestic generic pharmaceutical companies began to enter the era of micro-profits has gradually become a consensus.
generic drugs into the era of micro-profits, how should pharmaceutical companies deal with it? (Photo source: Pharmaceutical Network) In fact, under the influence of policies such as "4 plus 7" volume procurement, medical insurance control fees, two-vote system, the sales volume and price of products of many enterprises have fallen sharply.
E.g. the results of the third batch of national organization drug centralized procurement proposed results show that the effective price reduction of enterprises concentrated in the distribution of 50% to 80%, there are also a number of enterprises fell by more than 90%, according to incomplete statistics, to be included in 56 varieties of at least 14 "one dime" varieties.
, Chongqing Corey Pharmaceuticals even fell by 92%, pulling the price of metformin (250mg) down to one-and-a-half.
under the enormous pressure of sales and profits, companies have to start measuring their own development strategies.
In this regard, the industry believes that pharmaceutical companies want to highlight the heavy siege, should actively adjust the sales team, reduce sales costs, improve production lines, and strive to achieve the integration of raw material preparations, reduce generation costs, enrich product categories, improve the ability of enterprises to resist risks, strengthen the research and development of innovative drugs, to achieve the transformation and upgrading of enterprises.
of the above, in order to survive in the future pharmaceutical environment, the combination of imitation and independent innovation are the path to explore.
In fact, because in the past a long time, China has been mainly generic drugs, so enterprises want to change to innovative pharmaceutical companies before for some reason, most will choose the "copy combination" of the development path.
For example, in July 2020, Asia Pacific Pharmaceuticals, in response to questions from investors, said that the company will adhere to the "combination of imitation, innovation-driven" development strategy, actively carry out high-end generic drugs, innovative drug research and development work, research and development focus on anti-tumor, anti-infection and other core areas, with independent intellectual property rights to improve the development of new drugs, layout of new preparations.
fact, innovation is the industry consensus, whether it is a combination of imitation and independent innovation.
, but it's worth noting that the small profits of generics don't mean that the innovation drug circuit is a good idea.
industry experts believe that China's pharmaceutical industry drug research and development too much convergence, too much convergence research and development will waste human and material resources, which deserves attention.
to the research and development of hot PD-1 as an example, the current domestic has approved 3, there are more than 30 queues.
, according to incomplete statistics, the current domestic research PD-(L)1 products of enterprises there are hundreds in the layout.
addition, talent is also an important challenge in the transformation path of pharmaceutical companies.
industry pointed out that if companies take the path of innovation, it will be limited to research and development talent and research and development investment two important factors.
, enterprises in the development of innovation not only have a good top-level design, the right direction of continuous efforts, but also need the enterprise's internal skills and their own perfect personnel training system.